您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Daminozide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Daminozide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Daminozide图片
CAS NO:1596-84-5
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
25g电议
50g电议

产品介绍
Daminozide 是一种植物生长调节剂,是人 KDM2/7 组蛋白去甲基化酶的选择性抑制剂,对 PHF8、KDM2A 和 KIAA1718 的 IC50 分别为 0.55、1.5 和 2.1 μM。 Daminozide 对 KDM2/7 亚家族的选择性与其他测试的去甲基化酶亚家族成员相比具有 >100 倍的选择性。
Cas No.1596-84-5
别名丁酰肼
化学名4-(2,2-dimethylhydrazinyl)-4-oxobutanoic acid
Canonical SMILESCN(C)NC(=O)CCC(=O)O
分子式C6H12N2O3
分子量160.17
溶解度DMF: 5 mg/ml,DMSO: 11 mg/ml,PBS (pH 7.2): 2 mg/ml
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Daminozide, a plant growth regulator, selectively inhibits the KDM2A with IC50 value of 1.5 μM, PHF8 with IC50 value of 0.55 μM, KDM7A with IC50 value of 2 μM.[1]
FBXL11/KDM2A is a histone H3 lysine 36 demethylase enzyme which enzymatic activity relies on a conserved JmjC domain in the N-terminus of the protein that coordinates iron and alphaketoglutarate to catalyze demethylation via a hydroxylation based mechanism.[2] The ZF-CxxC DNA binding domain within FBXL11/KDM2A has the capacity to interact with non-methylated DNA and can target to CpG island regions of the genome where it specifically removes histone H3 lysine 36 methylation.[3] This mechanism acts to create a chromatin environment at CpG islands that highlights these regulatory elements and differentiates them from non-regulatory regions in large complex mammalian genomes. In a study in mouse hepatocytes, this gene was shown to regulate hepatic gluconeogenesis.[4]
Histone Nε-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. Lung cancer is the leading cause of cancer deaths in the United States and worldwide. Non–small cell lung cancer (NSCLC)accounts for about 85% of all lung cancer cases, and its molecular etiology is heterogeneous[5]. Klaus W. et al [6] found that KDM2A overexpression in NSCLC cells increased cell proliferation and invasiveness.And KDM2A knockdown abrogated tumor growth and invasive abilities of NSCLC cells in mouse xenograft models, suggesting that KDM2A may be a promising therapeutic target in NSCLC.Daminozide, as a KDM2A selective inhibitor, was once widely used as a plant growth retardant but now will be a potent approach to targeted therapies for NSCLC.[7]
References:
1.Nathan R. Rose. et al. Plant Growth Regulator Daminozide Is a Selective Inhibitor of Human KDM2/7 Histone Demethylases. Journal of Medicinal Chemistry. J. Med. Chem. 2012, 55: 6639−6643.
2.Tsukada Y. et al. "Histone demethylation by a family of JmjC domain-containing proteins". Nature 2006, 439 (7078): 811–6.
3.Blackledge NP. et al. "CpG islands recruit a histone H3 lysine 36 demethylase". Molecular Cell 2010, 38 (2): 179–90..
4.Pan D, Mao C. et al. "The Histone Demethylase Jhdm1a Regulates Hepatic Gluconeogenesis". PLOS Genetics,2012, 8 (6): e1002761.
5.Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–1380.
6.Klaus W.et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 2013,123(12):5231-5246.
7.Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181.